XNAS
VINC
Market cap251kUSD
May 19, Last price
0.05USD
1D
-12.55%
1Q
-96.27%
IPO
-99.55%
Name
Vincerx Pharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-18.24%
Rev. gr., 5y
%
Revenues
0k
Net income
-30m
L-25.11%
CFO
-26m
L-35.41%
Earnings
Aug 06, 2025
Profile
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 31,463 | 43,524 | 72,044 | |||
Unusual Expense (Income) | ||||||
NOPBT | (31,463) | (43,524) | (72,044) | |||
NOPBT Margin | ||||||
Operating Taxes | (8,207) | |||||
Tax Rate | ||||||
NOPAT | (31,463) | (43,524) | (63,837) | |||
Net income | (30,074) -25.11% | (40,157) -29.75% | (57,160) 266.22% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 17,874 | 114 | 280 | |||
BB yield | -3,583.44% | -0.45% | -1.31% | |||
| Debt | ||||||
Debt current | 2,324 | 1,024 | ||||
Long-term debt | 3,842 | 5,848 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 50 | 50 | ||||
Net debt | (4,987) | (6,616) | (45,587) | |||
| Cash flow | ||||||
Cash from operating activities | (26,127) | (40,453) | (59,604) | |||
CAPEX | ||||||
Cash from investing activities | 212 | 41,500 | (40,578) | |||
Cash from financing activities | 17,992 | 114 | 280 | |||
FCF | (29,137) | (42,609) | (62,896) | |||
| Balance | ||||||
Cash | 4,987 | 12,782 | 52,459 | |||
Long term investments | ||||||
Excess cash | 4,987 | 12,782 | 52,459 | |||
Stockholders' equity | (189,067) | (159,102) | (121,362) | |||
Invested Capital | 191,791 | 174,695 | 172,516 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 1,898 | 21,295 | 21,029 | |||
Price | 0.26 -77.73% | 1.18 15.69% | 1.02 -89.99% | |||
Market cap | 499 -98.01% | 25,128 17.15% | 21,450 -87.74% | |||
EV | (4,488) | 18,512 | (24,137) | |||
EBITDA | (30,373) | (42,609) | (71,105) | |||
EV/EBITDA | 0.15 | 0.34 | ||||
Interest | 8,207 | |||||
Interest/NOPBT | ||||||